A number of other research firms also recently commented on ARAV. Piper Jaffray Companies boosted their target price on shares of Aravive from $15.00 to $36.00 and gave the stock an overweight rating in a report on Tuesday, November 19th. Robert W. Baird upgraded shares of Aravive from a neutral rating to an outperform rating in a report on Monday. HC Wainwright restated a buy rating and issued a $31.00 price target (up previously from $18.00) on shares of Aravive in a research report on Wednesday, November 20th. Zacks Investment Research cut Aravive from a buy rating to a hold rating in a report on Thursday, October 24th. Finally, Wedbush increased their price objective on Aravive from $12.00 to $28.00 and gave the company an outperform rating in a research report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. The company has an average rating of Buy and an average target price of $24.44.
Shares of Aravive stock opened at $11.53 on Tuesday. Aravive has a 52 week low of $3.07 and a 52 week high of $15.62. The company has a current ratio of 7.59, a quick ratio of 7.59 and a debt-to-equity ratio of 0.18. The stock has a market cap of $108.86 million, a PE ratio of -1.08 and a beta of 2.35. The company’s 50-day moving average price is $7.44 and its two-hundred day moving average price is $6.53.
In other Aravive news, CEO Jay Shepard sold 4,004 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $6.82, for a total transaction of $27,307.28. Also, Director Srinivas Akkaraju acquired 133,333 shares of Aravive stock in a transaction on Monday, December 2nd. The shares were purchased at an average cost of $11.30 per share, with a total value of $1,506,662.90. Company insiders own 39.80% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Aravive by 4.7% in the second quarter. Vanguard Group Inc. now owns 159,034 shares of the company’s stock worth $955,000 after acquiring an additional 7,200 shares in the last quarter. BlackRock Inc. lifted its position in shares of Aravive by 5.8% in the 2nd quarter. BlackRock Inc. now owns 173,943 shares of the company’s stock valued at $1,044,000 after acquiring an additional 9,544 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Aravive by 13.8% in the 2nd quarter. Renaissance Technologies LLC now owns 148,265 shares of the company’s stock valued at $890,000 after acquiring an additional 18,017 shares in the last quarter. Finally, Artal Group S.A. lifted its position in shares of Aravive by 20.0% in the 2nd quarter. Artal Group S.A. now owns 307,466 shares of the company’s stock valued at $1,845,000 after acquiring an additional 51,197 shares in the last quarter. Institutional investors own 30.85% of the company’s stock.
Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.
See Also: Quiet Period Expirations Explained
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.